Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 20;9:1073503. doi: 10.3389/fcvm.2022.1073503

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Quarta, Fontana, Damy, Catini, Simoneau, Mercuri, Garcia-Pavia, Maurer and Palladini.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

(A) Schematic diagram depicting the 3 anti-fibril mAb therapies currently under investigation for AL amyloidosis and (B) Schematic diagram depicting the 2 anti-fibril mAb therapies currently under investigation for ATTR amyloidosis. In (A) this schematic figure shows the 3 mAbs currently under investigation for depletion of light-chain fibrils in AL amyloidosis. In (B) this schematic figure shows the 2 mAbs currently under investigation for depletion of TTR fibrils in ATTR amyloidosis. AL, light chain amyloidosis; IgG1, immunoglobulin G1; mAb, monoclonal antibody.